Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma
详细信息 查看全文
- 作者：Francesca Romana Ponziani ; Sherrie Bhoori ; Alessandro Germini ; Marco Bongini ; Maria Flores ; Carlo Sposito ; Antonio Facciorusso ; Antonio Gasbarrini and Vincenzo Mazzaferro
- 刊名：Liver International
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：36
- 期：7
- 页码：1033-1042
- 全文大小：308K
- ISSN：1478-3231
文摘
Various grades of adverse events are associated with sorafenib and have recently been considered as a surrogate of response in patients with advanced hepatocellular carcinoma. The aim of this prospective study was to measure the efficacy of a sorafenib dose reduction regimen, adjusted on patient's tolerability, and aimed at increasing the exposure to the drug.